Images provided by Cardiatis
Introduction to the technology
MULTILAYER TECHNOLOGY PLATFORM
Cardiatis Multilayer Technology platform is based on the patented proprietary technique of multilayer braiding of cobalt alloys to develop stents with spatial three dimensional geometrical structures. The main advantage of the 3D multilayer technology platform lies in the fact that it makes it possible to modulate hemodynamic flow within the affected arterial segment. The multilayer stent design, by virtue of its 3D geometry, reduces flow velocity within the aneurysm vortex while improving laminar flow in the main artery and surrounding vital branches. This allows for reduction of stress on the wall of the aneurysmal sac, stasis and the formation of an organized thrombus. The 3D multilayer technology platform is applied across aneurysms in many locations including cerebral, aortic and peripheral. Concept and clinical effects of the 3D multilayer stent technology have been proven in-silico, in-vitro, in-vivo and clinically.
Patients with thoracoabdominal aortic aneurysm (TAAA) have been classically managed by open surgical repair, but despite surgical advances and the introduction of newer less-invasive techniques, such as hybrid repair or branched endografts, these patients remain a surgical challenge. The high incidence and severity of complications and failure to reproduce acceptable outcomes outside of high volume centers has fueled the drive for a less invasive, more efficacious, and more universally reproducible solution for TAAA repair. Disruptive technology with Multilayer Flow Modulator (MFM) stents is emerging as an alternative to abrupt aneurysm exclusion and is an unorthodox concept for the management of aneurysmal disease. The MFM stents are self-expanding mesh constructs of cobalt alloy wires interconnected in 5 layers. They are extremely flexible devices with high kinking and fatigue resistance and low total porosity due to their interlocking layers. The construct channels blood flow to native side branches and slows the flow vortices within the aneurysm sac, thus laminating blood flow. Through this mechanism of flow modulation, the MFM device treats the aneurysm rather than excluding it. The MFM has the advantage of being simple and easy to deploy, and its minimal invasiveness allows for negligible impact on patients’ comorbid status, rendering it ideal for use in high-risk polymorbid patients.